Chinese consensus on the management of liver cirrhosis

Liver cirrhosis, characterized by diffuse necrosis, insufficient regeneration of hepatocytes, angiogenesis, severe fibrosis, and the formation of pseudolobules, is a progressive, chronic liver disease induced by a variety of causes. It is clinically characterized by liver function damage and portal hypertension, and many complications may occur in its late stage. Based on the updated practice guidelines, expert consensuses, and research advances on the diagnosis and treatment of cirrhosis, the Chinese Society of Gastroenterology of Chinese Medical Association established the current consensus to standardize the clinical diagnosis and management of liver cirrhosis and guide clinical practice. This consensus contains 43 statements on the etiology, pathology and pathogenesis, clinical manifestations, major complications, diagnosis, treatment, prognosis, and chronic disease control of liver cirrhosis. Since several practice guidelines and expert consensuses on the complications of liver cirrhosis have been published, this consensus emphasizes the research progress of liver cirrhosis itself.

• Publication year

  2024

• Venue

  Journal of Digestive Diseases

• Publication date

  2024-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1751-2980.13294PMID 39044465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Investigate of the etiology and prevention status of liver cirrhosis].

  2023cited by this paper
• Prevalence and risk factors of covert hepatic encephalopathy in cirrhotic patients: A multicenter study in China

  2023cited by this paper
• Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): A nationwide cohort study

  2023cited by this paper
• Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China

  2023cited by this paper
• Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a Phase 2 randomized controlled trial.

  2022cited by this paper
• Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

  2022influential reference
• Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.

  2022cited by this paper
• Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis

  2022cited by this paper
• Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-Controlled Trials.

  2022cited by this paper
• EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.

  2022cited by this paper
• A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study

  2022cited by this paper
• [Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)].

  2022cited by this paper
• Impact of Cirrhotic Cardiomyopathy Diagnosed According to Different Criteria on Patients with Cirrhosis Awaiting Liver Transplantation: A Retrospective Cohort Study

  2022cited by this paper
• Acute-on-Chronic Liver Failure Clinical Guidelines

  2022cited by this paper
• Skeletal Muscle Alterations Indicate Poor Prognosis in Cirrhotic Patients: A Multicentre Cohort Study in China

  2022cited by this paper
• Baveno VII - Renewing consensus in portal hypertension.

  2021cited by this paper
• Evidence-based clinical practice guidelines for Liver Cirrhosis 2020

  2021influential reference
• Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

  2021cited by this paper
• L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial

  2021cited by this paper
• Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression

  2021cited by this paper
• Management of the major complications of cirrhosis: Beyond guidelines.

  2021cited by this paper
• Determinants of re‐compensation in patients with hepatitis B virus‐related decompensated cirrhosis starting antiviral therapy

  2021cited by this paper
• Liver cirrhosis.

  2021cited by this paper
• Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China

  2021cited by this paper
• [Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition)].

  2021cited by this paper
• Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome

  2021cited by this paper
• Speckle Tracking Analysis Reveals Altered Left Atrial and Ventricular Myocardial Deformation in Patients with End-Stage Liver Disease

  2021cited by this paper
• Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases

  2021cited by this paper
• Abnormal cholesterol metabolism underlies relative adrenal insufficiency in decompensated cirrhosis

  2021cited by this paper
• New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.

  2021influential reference
• Acute-on-chronic liver failure: A distinct clinical syndrome.

  2021cited by this paper
• Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)

  2021cited by this paper
• Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update.

  2021cited by this paper
• Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy

  2020cited by this paper
• Redefining Cirrhotic Cardiomyopathy for the Modern Era

  2020cited by this paper
• Including Relative Adrenal Insufficiency in Definition and Classification of Acute on Chronic Liver Failure.

  2020cited by this paper
• Development and validation of a radiomics signature as a non‐invasive complementary predictor of gastroesophageal varices and high‐risk varices in compensated advanced chronic liver disease: A multicenter study

  2020cited by this paper
• Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data.

  2020cited by this paper
• Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis

  2020cited by this paper
• ALTERATIONS IN GUT MICROBIOME IN CIRRHOSIS AS ASSESSED BY QUANTITATIVE METAGENOMICS. RELATIONSHIP WITH ACUTE-ON-CHRONIC LIVER FAILURE AND PROGNOSIS.

  2020influential reference
• Management of Gallstones and Acute Cholecystitis in Patients with Liver Cirrhosis: What Should We Consider When Performing Surgery?

  2020influential reference
• Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence

  2020cited by this paper
• Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

  2020cited by this paper
• Bacterial infection triggers and complicates acute-on-chronic liver failure in patients with hepatitis B virus-decompensated cirrhosis: A retrospective cohort study

  2020influential reference
• The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods

  2019cited by this paper
• Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension.

  2019cited by this paper
• [Clinical guidelines on nutrition in end-stage liver disease].

  2019cited by this paper
• Beta-blockers in cirrhosis: Evidence-based indications and limitations

  2019cited by this paper
• Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

  2019cited by this paper
• Guideline for diagnosis and treatment of liver failure (2018)

  2019cited by this paper
• EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

  2019cited by this paper
• Combined Scores from the EncephalApp Stroop Test, Number Connection Test-B, and Serial Dotting Test Accurately Identify Patients with Covert Hepatic Encephalopathy.

  2019cited by this paper
• [Chinese guidelines on the management of liver cirrhosis].

  2019cited by this paper
• Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival

  2019cited by this paper
• Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2019cited by this paper
• Vascular Targets for the Treatment of Portal Hypertension

  2019cited by this paper
• [Guideline for diagnosis and treatment of liver failure].

  2019cited by this paper
• β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.

  2019cited by this paper
• [Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update].

  2019cited by this paper
• The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases.

  2019influential reference
• Burden of liver diseases in the world.

  2019cited by this paper
• Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)

  2018cited by this paper
• [Consensus on clinical application of hepatic venous pressure gradient in China (2018)].

  2018cited by this paper
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

  2018cited by this paper
• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.

  2018cited by this paper
• Antifibrotics in liver disease: are we getting closer to clinical use?

  2018cited by this paper
• [Guidelines for the diagnosis and management of hepatic encephalopathy in cirrhosis].

  2018cited by this paper
• [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update].

  2018cited by this paper
• Response to the clinical course and short‐term mortality of cirrhotic patients with non‐spontaneous bacterial peritonitis infections

  2017influential reference
• Mechanisms of hepatic stellate cell activation

  2017cited by this paper
• Hepatic hydrothorax: An update and review of the literature

  2017cited by this paper
• Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases

  2017cited by this paper
• Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

  2017cited by this paper
• Liver Sinusoidal Endothelial Cell: An Update

  2017cited by this paper
• Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.

  2017cited by this paper
• Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.

  2017cited by this paper
• Portal vein thrombosis: The role of imaging in the clinical setting.

  2017cited by this paper
• Results of Portosystemic Shunt Embolization in Selected Patients with Cirrhosis and Recurrent Hepatic Encephalopathy.

  2017cited by this paper
• The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells

  2017influential reference
• [Guidelines on the management of ascites and complications in cirrhosis].

  2017cited by this paper
• Good for the lung but bad for the liver? Garlic‐induced hepatotoxicity following liver transplantation

  2017cited by this paper
• Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.

  2017cited by this paper
• Computed tomography in evaluating gastroesophageal varices in patients with portal hypertension: A meta-analysis.

  2016cited by this paper
• Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

  2016cited by this paper
• Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.

  2016cited by this paper
• Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study

  2016cited by this paper
• Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

  2016cited by this paper
• Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial.

  2016cited by this paper
• Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.

  2016cited by this paper
• Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients

  2015cited by this paper
• Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

  2015cited by this paper
• Does low‐dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study

  2015cited by this paper
• Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

  2015cited by this paper
• Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites

  2015cited by this paper
• Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

  2015cited by this paper
• Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.

  2015influential reference
• Role of Transjugular Intrahepatic Portosystemic Shunts in the Management of Hepatopulmonary Syndrome: A Systemic Literature Review.

  2015cited by this paper
• Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

  2014cited by this paper
• Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.

  2014cited by this paper
• Alterations of the human gut microbiome in liver cirrhosis

  2014influential reference

• From "Form" to "Essence": Guiding Students to Achieve Deep Cognitive Transition in Morphological Experiments.

  2026cites this paper
• Ultrasound-based assessment of impaired gastric emptying in patients with hepatitis B cirrhosis

  2025cites this paper
• Estimating liver cirrhosis severity with extracellular volume fraction by spectral CT

  2025cites this paper
• Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma

  2025cites this paper
• Diagnostic Value and Prognostic Effect of miR-7-5p in Cirrhosis

  2025cites this paper
• Machine learning-based plasma metabolomics for improved cirrhosis risk stratification

  2025cites this paper
• Alterations in the gut microbiota of alcoholic cirrhosis patients infected with Clonorchis sinensis in the Pearl River Delta region of China

  2025cites this paper
• Exploring the mechanism of action of Jinqiancao granules against liver cirrhosis based on the liver-gut axis

  2025cites this paper
• Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia

  2025cites this paper
• Correlation analysis of serum TIP30 mRNA expression with recompensation and short-term prognosis in the patients with hepatitis B virus-derived decompensated liver cirrhosis.

  2025cites this paper
• Association Between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Short-Term Progression of Carotid Atherosclerosis Among Early Middle Age Adults

  2025cites this paper
• New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target.

  2025cites this paper
• Psychological Resilience as a Mediator between Childhood Trauma and Adult Mental Health

  year unknowncites this paper